Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer | OncLive

Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer

March 17, 2017

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

In the adjuvant setting, tumor biomarkers can provide an indication of the present of future behavior of a cancer. Multiple tests exist to measure these biomarkers, but the question among clinicians is: which test should be ordered?

In the adjuvant setting, 3 tumor biomarker tests—Prosigna, EndoPredict and Breast Cancer Index—have shown significant clinical utility, says Hayes. These multi-parameter assays measure either transcript or protein expression and have demonstrated analytic validity for prognosis in patients with ER-positive/HER2-negative, node-negative breast cancer.

<<<

View more from the St. Gallen's Breast Cancer Conference


x